Biomerieux SA
PAR:BIM
Intrinsic Value
bioMérieux SA engages in the provision of in vitro diagnostic solutions, which determine the source of disease and contamination. [ Read More ]
The intrinsic value of one BIM stock under the Base Case scenario is 98.09 EUR. Compared to the current market price of 99.2 EUR, Biomerieux SA is Overvalued by 1%.
Valuation Backtest
Biomerieux SA
Run backtest to discover the historical profit from buying and selling BIM stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Biomerieux SA
Current Assets | 2.2B |
Cash & Short-Term Investments | 65.3m |
Receivables | 944.3m |
Other Current Assets | 1.2B |
Non-Current Assets | 3.1B |
Long-Term Investments | 220.2m |
PP&E | 1.5B |
Intangibles | 1.2B |
Other Non-Current Assets | 100.4m |
Current Liabilities | 1.1B |
Accounts Payable | 265.1m |
Short-Term Debt | 10m |
Other Current Liabilities | 812.2m |
Non-Current Liabilities | 419.7m |
Long-Term Debt | 355.4m |
Other Non-Current Liabilities | 64.3m |
Earnings Waterfall
Biomerieux SA
Revenue
|
3.7B
EUR
|
Cost of Revenue
|
-1.6B
EUR
|
Gross Profit
|
2.1B
EUR
|
Operating Expenses
|
-1.6B
EUR
|
Operating Income
|
439m
EUR
|
Other Expenses
|
-81.4m
EUR
|
Net Income
|
357.6m
EUR
|
Free Cash Flow Analysis
Biomerieux SA
BIM Profitability Score
Profitability Due Diligence
Biomerieux SA's profitability score is 57/100. The higher the profitability score, the more profitable the company is.
Score
Biomerieux SA's profitability score is 57/100. The higher the profitability score, the more profitable the company is.
BIM Solvency Score
Solvency Due Diligence
Biomerieux SA's solvency score is 69/100. The higher the solvency score, the more solvent the company is.
Score
Biomerieux SA's solvency score is 69/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BIM Price Targets Summary
Biomerieux SA
According to Wall Street analysts, the average 1-year price target for BIM is 116.66 EUR with a low forecast of 90.9 EUR and a high forecast of 134.4 EUR.
Shareholder Return
BIM Price
Biomerieux SA
Average Annual Return | 11.87% |
Standard Deviation of Annual Returns | 28.66% |
Max Drawdown | -44% |
Market Capitalization | 11.7B EUR |
Shares Outstanding | 118 160 000 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
bioMérieux SA engages in the provision of in vitro diagnostic solutions, which determine the source of disease and contamination. The company is headquartered in Craponne, Auvergne-Rhone-Alpes and currently employs 13,076 full-time employees. The company went IPO on 2004-06-07. The firm designs, develops, manufactures and sells systems used in clinical applications, such as for the diagnosis of tuberculosis, respiratory infections, among others and industrial applications, such as for the analysis of industrial or environmental samples. The firm also provides its customers with related services for the installation and maintenance of instruments, and training for product users. BioMerieux SA operates through its numerous subsidiaries in various countires, including bioMerieux Deutschland GmbH, bioMerieux Austria GmbH, Advencis, bioMerieux Benelux SA/NV, as well as BioFire Diagnostics Inc., chromID CARBA SMART and new bi-plate Petri dish.
Contact
IPO
Employees
Officers
The intrinsic value of one BIM stock under the Base Case scenario is 98.09 EUR.
Compared to the current market price of 99.2 EUR, Biomerieux SA is Overvalued by 1%.